Brain tumour immunology and therapy group

Main content

Professor Martha Chekenya Enger

Welcome to the Brain Tumor Immunology & Therapy group

The group is led by Dr Martha Chekenya Enger and is one of five groups that form the larger Translational Cancer and Vascular Unit

Publications (PubMed)

BTi - Moving Basic Research Closer To the Clinic


American Association for Cancer Research (AACR 2024) April 5-10, 2024

It was a great privilege to participate at ‘AACR Annual Meeting 2024’, a large and important conference for cancer research, the place where scientists, clinicians, survivors, and patients, gather to share and discuss the latest breakthroughs.

hampered progress of clinical trials in oncology

The effect of the COVID-19 pandemic on clinical brain cancer trials

2020 evolved into an annus horribilis for everyone, manifested by physical distancing and social isolation, disrupted work routines and for many, tragic loss of livelihood and loved ones.

Marianne Hjellvik Hannisdal winning best poster prize, congratulated by dean Marit Bakke

Best poster prize at the medical faculty´s research day

We congratulate Marianne Hjellvik Hannisdal for this accolade, winning best poster prize at the medical faculty‘s research day, with over 30 talented phd fellows who presented their excellent research projects in the form of poster presentations!

User involvement
Hjernesvulstforeningen besøker Brain tumor Immunology and Therapy Group hos Instituttet for biomedisin

Patient organization collaborates with researchers to improve brain cancer therapy

The research laboratory for brain cancer immunology and therapy at the Department of Biomedicine has received the secretary general of the Brain-Tumour Society Rolf Ledal to discuss current and future research projects.

Research project
Logo Hjernesvulstforeningen

Bortezomib and Temozolomide in Recurrent Glioblastoma With Unmethylated MGMT Promoter

This phase IB/II trial is designed to investigate the safety and survival benefits for patients with recurrent glioblastoma with unmethylated MGMT promoter treated with Bortezomib and Temozolomide in a specific schedule.